Moderna Cancer Vaccine Trial News Boosts Stock Over 120%

Moderna and Merck announced on Wednesday that their collaborative personalized mRNA-based cancer vaccine, administered alongside Merck's immunotherapy drug Keytruda, has successfully met its primary objectives in a late-stage clinical trial. This significant development marks the first positive Phase 3 outcome for any personalized cancer therapy, any mRNA-based cancer therapy, and any treatment demonstrating a meaningful improvement over the use of Keytruda alone. The ongoing trial, designated as a Phase 3 study, involves 1,137 patients diagnosed with high-risk melanoma that has undergone surgical removal. Early results from this trial indicate that the combination therapy achieved its primary endpoint by reducing the risk of cancer recurrence. Furthermore, it met its secondary endpoint, which focused on lowering the risk of the cancer spreading to other parts of the body. The market reacted swiftly and positively to this news, with shares of Moderna Inc. (Nasdaq: MNRA) experiencing a surge of over 120% in early trading on Wednesday. At the time of reporting, Moderna's stock price reached a high not observed since mid-2024. Merck & Co Inc. (NYSE: MRK), the partner company, saw a more moderate increase in its stock price, rising by 11%. The personalized mRNA cancer vaccine, named Intismeran Autogene, operates by first sequencing and analyzing the DNA of a patient's surgically removed tumor to identify its unique mutations. A custom vaccine is then constructed, specifically tailored to these individual mutations. This personalized vaccine's purpose is to train the patient's immune system to recognize and target these specific cancer markers. When combined with Keytruda, an immunotherapy medicine, the treatment aims to enhance the body's ability to detect and combat cancer cells more effectively. Stéphane Bancel, CEO of Moderna, stated in a company release that these Phase 3 findings represent a "pivotal moment for the field of cancer research." He further elaborated that the concept of creating an mRNA treatment designed for an individual patient's cancer, once aspirational, is now becoming a reality. The collaboration between Moderna and Merck is currently evaluating this combination therapy in nine ongoing clinical trials. These trials span various tumor types and disease stages, including investigations into its efficacy for lung cancer, bladder cancer, and kidney cancer, indicating a broad potential application for this novel treatment approach.